Zydus Life gets tentative USFDA approval for Letermovir tablets

The company announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) to market Letermovir tablets.

Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant or kidney transplant.

The drug (USRLD: Prevymis tablets), available in 240 mg and 480 mg variants, are set to be manufactured at the company's formulation manufacturing facility in Ahmedabad SEZ, India. It had annual sales of $289.5 million in the United States.

The group now has 393 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The pharmaceutical company reported 26.76% increase in consolidated net profit of Rs 789.6 crore on 5.83% rise in revenue from operations to Rs 4,343.70 crore in Q3 FY24 over Q3 FY23.

Shares of Zydus Lifesciences rose 0.79% to close at Rs 999.50 on Friday, 22nd March.

Powered by Capital Market - Live News